RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers

(MedPage Today) -- The RET inhibitor selpercatinib (Retevmo) exhibited clinical activity in almost half of patients with non-lung/non-thyroid cancers associated with RET gene fusions, according to a subgroup analysis of a randomized trial.
Objective...